JVC Home \ Comprehensive Education \JVC News \ August 14, 2003
Toledo, OH—August 14, 2003- JVC received FDA approval to embark upon the TOLEDO Study, a national clinical research trial of catheter-directed thrombolysis versus anticoagulation for patients with iliofemoral DVT. The standard treatment for patients with extensive deep venous thrombosis in the United States is anticoagulation alone. Clinicians at JVC, as well as venous disease experts across the country, have recognized the benefit of a strategy of clot removal in addition to effective anticoagulation in reducing the severe morbidity of the post-thrombotic syndrome.

Investigators plan to enroll 150 patients at 30 sites into this nationwide trial. The primary endpoints are early clot resolution and patient quality of life at one year. Patients will also be evaluated for ongoing post-thrombotic morbidity, valve function, and incidence of recurrent venous thromboembolic disease.

For more information about the TOLEDO Study, click here.
 
 
Untitled Document
This website is optimized for IE 5.0 and Netscape 4.0 or higher. You must allow pop-ups the entire site for some links to activate properly. You must also have Macromedia Flash and Adobe Reader to view some page elements. They can be downloaded from here.

(C) 1998-2006 Jobst Vascular Center / ProMedica Health System. All rights reserved.